DexCom, Inc. (DXCM)

On our long-only desk, we are seeing strong fundamental tailwinds following DexCom's Q2 report. The company successfully raised its full-year 2026 revenue guidance to the $5.18 billion to $5.25 billion range alongside higher margin expectations. However, with the stock trading roughly 16% higher post-earnings and approaching intrinsic value, our valuation models suggest a more cautious entry point despite the broader addressable market expansion into type 2 diabetes.

Watching the 50-day moving average and recent price action, DXCM's 37.2% year-to-date surge has significantly outperformed parts of the broader market, yet it lags behind the SandP 500's 52-week trailing return profile. The market is pricing in accelerated adoption of the G7 system and Stelo over-the-counter biosensor, but any macro consumer spending slowdown or multiple contraction could easily trigger short-term consolidation.

In our clinical practice, the push toward broader reimbursement by all four major U.S. commercial PBMs for type 2 diabetes non-insulin users—representing over 7 million covered lives—is fundamentally shifting patient management protocols. Precision continuous glucose monitoring is no longer restricted to intensive insulin therapies, giving platforms like the G7 and Dexcom ONE+ a massive structural adoption runway.

As a risk manager reviewing the recent 10-K filings, I am flagging structural regulatory and reimbursement headwinds that many equity bulls are discounting. The introduction of a new competitive bidding program and rental model is explicitly expected to reduce Medicare reimbursement for CGM systems starting in 2028. Coupled with an active FDA warning letter concerning manufacturing and quality systems, compliance overhead remains a notable execution risk.

On our options desk, we are monitoring how the post-earnings jump has altered volatility skews. With the stock up more than 16% on raised 2026 guidance, implied volatility has compressed slightly, making out-of-the-money put spreads an attractive and cost-effective overlay to hedge against any broader healthcare sector or macro rate-related pullbacks.